TCG CROSSOVER MANAGEMENT, LLC other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/27/2024

Adviser Type:

- Large advisory firm

Number of Employees:

11 22.22%

of those in investment advisory functions:

6 20.00%

Registration:

SEC, Approved, 12/18/2020

AUM:

2,196,110,899 128.10%

of that, discretionary:

2,196,110,899 128.10%

Private Fund GAV:

2,196,110,899 128.10%

Avg Account Size:

1,098,055,450 14.05%

SMA’s:

NO

Private Funds:

2 1

Contact Info

650 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
963M 825M 688M 550M 413M 275M 138M
2020 2021 2022 2023

Recent News

The Petri Dish: Flagship startup raises $126M, Binx gets FDA OK
04/01/2021

The round was led by Wellington Management Company and included participation from Redmile Group, TCG Crossover ... Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated ...

bizjournals.com

Entrada raises $116M to take DMD therapy into the clinic
03/31/2021

Entrada Therapeutics has raised $116 million to develop intracellular biologics. The series B round will enable Entrada to start clinical development of a pipeline featuring treatments for diseases such as Duchenne muscular dystrophy (DMD).

fiercebiotech.com

Entrada Therapeutics Announces Closing of $116 Million Series B Financing
03/31/2021

Wellington Management was joined by Redmile Group, TCG Crossover, Greenspring Associates ... Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital ...

oaoa.com

Entrada Therapeutics Closes $116M Series B Financing
03/31/2021

Wellington Management was joined by Redmile Group, TCG Crossover, Greenspring Associates ... Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated in the financing. Led by Dipal Doshi ...

finsmes.com

Entrada Therapeutics Announces Closing of $116 Million Series B Financing
03/31/2021

Wellington Management was joined by Redmile Group, TCG Crossover, Greenspring Associates ... Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital ...

benzinga.com

Entrada Therapeutics Announces Closing of $116 Million Series B Financing
03/31/2021

Wellington Management was joined by Redmile Group, TCG Crossover, Greenspring Associates ... Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital ...

digitaljournal.com


Private Funds Structure

Fund Type Count GAV
Other Private Fund 2 $2,196,110,899

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
PARK STREET CAPITAL ADVISERS, L.L.C. - - - - - - 842.5m 842.5m 842.5m 10
JANICZEK WEALTH MANAGEMENT - - - - - - 59.4m 59.4m 1.1b 1
PITON INVESTMENT MANAGEMENT, LP - - - - - - 33.6m 33.6m 920.4m 1
BENEFIT FINANCIAL SERVICES GROUP - - - - - - - - 1.1b -
LIBERTY WEALTH MANAGEMENT, LLC - - - - - - 7.0m 7.0m 1.2b 1
OCCUDO QUANTITATIVE STRATEGIES LP - - - - - - 2.7m 2.7m 851.2m 1
ANDERSON HOAGLAND & CO - - - - - - 21.5m 21.5m 1.1b 2
PARKSIDE INVESTMENTS, LLC - - - - - - 47.7m 47.7m 1.2b 2
AUBREY CAPITAL MANAGEMENT - - - - - - 43.5m 43.5m 841.6m 1
LEGATO CAPITAL MANAGEMENT, LLC - - - - - - 115.9m 115.9m 1.0b 1

Private Funds



Employees




Brochure Summary

Overview

ADVISORY BUSINESS A. TCG Crossover Management, LLC (“TCGX” or the “Firm”), a Delaware limited liability company, is an investment adviser located in Palo Alto, CA. Chen Yu is TCGX’s principal owner. B. As an investment adviser, TCGX provides investment advisory services to pooled investment vehicles (each a “Fund” or collectively, the “Funds”). The Funds are exempt from registration under the Investment Company Act of 1940, as amended (the “Investment Company Act”), pursuant to Sections 3(c)(7) of the Investment Company Act. TCGX manages the assets of the Funds in accordance with the term sheets and other related agreements (herein, the “Offering Documents”). The Firm’s investment objective is to make investments in companies developing therapeutic drug products and invests
in both private and public assets. Information about TCGX’s advisory services is included in this Brochure and is qualified in its entirety by information contained in the Offering Documents. C. TCGX does not tailor its advisory services to the individual or particular needs of investors in the Funds. Such investors will accept the terms of advisory services as set forth in the Offering Documents. The Firm has broad investment authority with respect to the Funds and, as such, investors should consider whether the investment objectives of the Funds will be in line with their respective individual objectives and risk tolerance prior to investment. D. TCGX does not participate in wrap fee programs. E. As of December 31, 2023, TCGX has $2,196,110,899 in regulatory assets under management on a discretionary basis.